Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Merck
McKinsey
Colorcon
McKesson

Last Updated: April 8, 2020

DrugPatentWatch Database Preview

LOPINAVIR AND RITONAVIR Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Lopinavir And Ritonavir, and when can generic versions of Lopinavir And Ritonavir launch?

Lopinavir And Ritonavir is a drug marketed by Lannett Co Inc and is included in one NDA.

The generic ingredient in LOPINAVIR AND RITONAVIR is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.

Drug patent expirations by year for LOPINAVIR AND RITONAVIR
Recent Clinical Trials for LOPINAVIR AND RITONAVIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ascletis Pharmaceuticals Co., Ltd.N/A
First Affiliated Hospital of Zhejiang UniversityN/A
Yonsei UniversityPhase 4

See all LOPINAVIR AND RITONAVIR clinical trials

Synonyms for LOPINAVIR AND RITONAVIR
(2S)-N-[(1S,3S,4S)-1-benzyl-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-pentyl]-3-methyl-2-(2-oxohexahydropyrimidin-1-yl)butanamide; thiazol-5-ylmethyl N-[(1S,2S,4S)-1-benzyl-2-hydroxy-4-[[(2S)-2-[[(2-isoprop
369372-47-4
ABT-378 & ABT-538
Aluvia
Aluvia(TM)
CHEBI:145924
D02498
DTXSID30190428
Kaletra (TN)
Kaletra(TM)
Lopimune
Lopinavir / Ritonavir
Lopinavir & Norvir
Lopinavir & Ritonavir
Lopinavir mixture with ritonavir
lopinavir-ritonavir
Lopinavir-Ritonavir mixt
Lopinavir/Ritonavir
LPV / RTV
LPV/r
LS-188000
Q3836750
Ritonavir and Lopinavir mixture
Ritonavir-boosted lopinavir
SCHEMBL1506739

US Patents and Regulatory Information for LOPINAVIR AND RITONAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lannett Co Inc LOPINAVIR AND RITONAVIR lopinavir; ritonavir SOLUTION;ORAL 207407-001 Dec 27, 2016 AA RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Merck
McKinsey
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.